Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is an example of a complex 18 disease of unknown etiology. Multiple studies point to disruptions in immune functioning in 19 ME/CFS patients as well as with specific genetic polymorphisms and alterations of the DNA 20 methylome in lymphocytes. However, the association between DNA methylation and genetic 21 background in relation to the ME/CFS is currently unknown. In this study we explored this 22 association by characterizing the genomic (~4.3 million SNPs) and epigenomic (~480 thousand 23 CpG loci) variability between populations of ME/CFS patients and healthy controls. We found 24 significant associations of methylation states in T-lymphocytes at several CpG loci and regions 25 with ME/CFS phenotype. These methylation anomalies are in close proximity to genes involved 26 with immune function and cellular metabolism. Finally, we found significant correlations of 27 genotypes with methylation phenotypes associated with ME/CFS. The findings from this study 28 highlight the role of epigenetic and genetic interactions in complex diseases, and suggest several 29 genetic and epigenetic elements potentially involved in the mechanisms of disease in ME/CFS.
Introduction
Understanding the biological basis of complex traits and diseases remains one of the 33 biggest challenges in biology and medicine. Chronic Fatigue Syndrome (also known as Myalgic 34
Encephalomyelitis, hereafter referred to as ME/CFS) is an example of a complex, multifactorial 35 disease with symptoms that vary substantially among patients. ME/CFS is a debilitating 36 multisystem disease affecting between 1 and 2 million people in the United States alone 1 , with 37 an annual economic impact between $17 and $24 billion 2 . Yet its biological basis remains 38 largely unknown. 39
Multiple studies point to disruptions in the immune and neuroendocrine systems in 40 ME/CFS patients [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . ME/CFS appears to be associated with specific genetic polymorphisms 15-41 17 , as well as with alterations of the DNA methylome in lymphocytes 14, 18, 19 . Understanding the 42 contribution of the genetic background in ME/CFS patients as a predisposing factor for 43 epigenetic abnormalities associated with the disease is a fundamental step to elucidate its causes. 44
This understanding is also key for the development of tools to identify risk factors and potential 45 treatments. 46 T-cell lymphocytes appear to be a primary cell type underlying immune and 47 neuroendocrine abnormalities observed in ME/CFS patients. Functional impairment in T-cell 48 glucocorticoid receptor and increased dexamethasone sensitivity are characteristic of some 49 ME/CFS patients 14, 20 . Furthermore, genetic polymorphisms within non-coding regions of T-cell 50 receptor loci 15 , as well as differential methylation in CD4 + T helper lymphocyte cells (Brenu et 51 al., 2014) , have been associated with the disease. The possible interactions between genomic and 52 T-cell epigenomic variation in ME/CFS remain unknown. 53
In this study, we aimed to explore the association between DNA methylation profiles of 54 T-cells and single nucleotide polymorphisms (SNPs) in ME/CFS patients. We quantified 55 lymphocyte proportions and isolated CD3 + T-cells (including both CD4 + T helper cells and CD8 + 56 T killer cells) via fluorescence activated cell sorting. We characterized the variation in genomic 57 (~4.3 million SNPs) and epigenomic (~480 thousand CpG loci) variability among ME/CFS 58 patients and healthy controls. Using this approach, we: 1) tested the association of genome-wide biological samples by the SolveCFS BioBank was ethically approved by the Genetic Alliance 69 ethics review board (IRB # IORG0003358) and the University of Toronto (IRB #27391), which 70 also approved all procedures for obtaining written informed consent from all participants in the 71 study. Two copies of the consent form were signed, with one copy provided to the participants 72 and one copy under secure storage at the SolveCFS Biobank. 73 Study population 74 In total, 61 ME/CFS diagnosed patients receiving care at the Bateman Horne Center, 75
Utah (46 females, 15 males) and 48 healthy control (36 females, 12 males) individuals were 76 recruited for this study. Female to male ratios were nearly identical in both cases and controls 77 (3:1). The sex ratio in our population of ME/CFS patients (cases) is consistent with previously 78 reported ratios indicating predominance of this illness in females 21-23 . Diagnosis of ME/CFS 79 was performed according to the 1994 Fukuda 24 and 2003 Canadian 25 criteria. To quantify 80 functional impairment, individuals completed the standardized health-related quality of life 81 survey RAND-36 26 . All individuals met the following criteria: 1) were HIV and Hepatitis-C 82 negative; and 2) had no intake history of immunomodulatory or immunosuppressive 83 medications. The Body Mass Index (BMI) of individuals ranged between 16.4 and 46 ( =27.2, 84 s=6.4), with no significant differences between case and control groups (t-test p=0.5; Wilcoxon 85 p=0.74) ( Fig. 1a) . Similarly, age, which ranged between 18 and 62 years ( =32.2, s=13.6), was 86 into principal components (PC) using the stats package in R. We excluded data from case and 140 control individuals with overlapping values along PC1 ( Fig. 3) , which explained ~80% of 141 variance in the RAND-36 data. In total, data from 30 individuals were excluded using this 142 approach: 18 cases (12 females, 6 males) and 12 controls (9 females, 3 males). These data were 143 re-analysed in PLINK. After excluding individuals with sub-optimal data, we identified and excluded data from 170 SNP loci that met one or more of the following criteria following 29,30 : 1) Rate of missing 171 genotypes was greater than 3% in PLINK (5% in GenABEL) ( Fig. 2c) ; 2) Rate of missing data 172 was significantly different (p < 0.00001) between cases and controls; 3) Allelic frequencies 173 significantly deviated from Hardy-Weinberg equilibrium (χ² p < 0.00001 in PLINK, FDR <0.2 in 174 GenABEL); and 4) Minimum allele frequency was smaller than 1% in PLINK (2% in 175 GenABEL). Out of 4,284,426 genotyped SNP loci, 1,779,031 SNP loci were excluded from 176 PLINK analyses, and 2,142,548 from GenABEL analyses. 177
We examined possible associations between SNP genotypes and ME/CFS disease 178 phenotypes (case or control) using χ2 testing as well as logistic regression tests that included 179 covariates of age, sex and BMI in both PLINK and GenABEL. To account for the uncertainty in 180 the potential genetic model of inheritance of ME/CFS, we performed multiple tests with different 181 underlying models: Genotypic, dominant, recessive, Cochram-Armitage trend, and allelic for the simple χ2 tests; and genotypic, dominant, recessive and multiplicative for logistic regressions.
and 2) Calculated corrected (empirical) p-values (family wise) after 10,000 permutations. We 187 generated spatial visualizations of raw p-values for all associations across chromosomes using 188 the program Haploview 36 . Due to the higher prevalence of ME/CFS in females than males 21-23 , 189 association tests were also performed in data from females only. Array Normalization 51 , which takes into account the differences between Infinium type I and II 237 probes. The level of methylation in each CpG locus was measured as beta-values, ranging from 0 238 to 1, which represent the proportion of methylation. In total, 467,971 CpG loci (out of 485,512) were retained for further analyses. 240
We examined possible associations between methylation levels at CpG loci and ME/CFS 241 disease phenotypes (case or control) through F-tests of logit-transformed beta-values 52 as 242 implemented in the dmpFinder function. To correct for potential confounding effects of multiple 243 methylation array batches (two in this study), as well as covariates of age, sex and BMI, we 244 utilized the empirical Bayes procedure implemented in the R package ComBat 53 . To assess 245 significance of associations (α = 0.05) we: 1) adjusted raw p-values for multiple testing by 246 performing Benjamini and Hochberg false discovery rate (FDR) corrections; and 2) calculated 247 empirical p-values after 10,000 permutations as described in 14 . In addition to testing for 248 associations at individual CpG loci, we performed tests of association at differentially 249 methylated genomic regions using the R package bumphunter as described in 54 scales between ME/CFS cases and healthy controls ( Fig. 1c-h) , there were no differences in the 277 relative proportions of cell types in the PBMC lymphocyte samples (Fig. 4) . Previous studies 278 investigating potential differences in the relative proportions of general lymphocyte types in 279 ME/CFS patients have produced incongruent results which have ranged from an increased 280 proportion of CD8+ T cells (Klimas et al., 1990) to no significant differences 7,64 . These 281 observations suggest that alterations of general lymphocyte type proportions may not be a 282 characteristic feature of ME/CFS. Rather, abnormalities in immune system functioning 283 associated with ME/CFS appear to involve alterations in the activity and abundance of specific 284 sub-populations 5,6,65 . 285 SNP Array 6.0 (n=42 ME/CFS, n=38 non-ME/CFS) and found 442 SNPs that were associated 327 with ME/CFS (P<3.3×10−5). The SNP that we found in significant association with ME/CFS in 328 females, rs11712777, was not included in any of these datasets. One SNP in the Schlauch et al. 329 (2016) data, rs1468604, is in linkage disequilibrium (LD) with rs11712777 (r 2 = 0.8716; 330
European population). The apparent discrepancy could be explained by the imperfect linkage 331 between the two SNPs, and therefore we recommend rs11712777 as a candidate for direct 332 genotyping in future studies. 333
There are no other overlaps in the SNPs or genes associated with ME/CFS between this 334 study and previous genetic association studies. This observation may be confounded by a 335 combination of multiple factors, including: 1) Differences in the types of arrays utilized in each 336 study (our study, with the largest genetic coverage to date, evaluated two-orders of magnitude 337 more SNPs than the Rajeevan (2015) study); 2) Differences among cohorts due to the wide 338 heterogeneity of ME/CFS; 3) Reduced statistical power to discriminate the effects of multiple genetic factors and ME/CFS. 343
Generalized gene-set analysis of the SNP data in MAGMA did not identify any gene-set 344 significantly enriched in either our data, or the data from Schlauch et al. (2016) . 345 346 Characterisation of SNP rs11712777 347 We used a variety of online reference resources to characterize the current knowledge of 348 rs11712777, and how it may influence ME/CFS phenotype (see Methods section). We also 349 examined SNPs in high LD with SNP rs11712777 (R 2 ≥0.8; Table 1 ). The Genotype-Tissue- Epigenetic associations with ME/CFS 377 Of the 467,971 CpG loci analysed, 141 had significant associations with the ME/CFS 378 phenotype (raw p-value < 0.05) and a mean percentage methylation difference between cases and 379 controls greater than 5% when data from both sexes were analysed together (Fig. 5c ). None of 380 these differentially methylated loci were significant after FDR corrections, however 133 had 381 significant empirical p-values < 0.05 calculated through permutation analyses (these are referred 382 to as differentially methylated probes -DMPs; Supplementary Table S1 ). Analyses of 383 methylation data from females alone indicated that 108 CpG loci had significant associations 384 with the ME/CFS phenotype (raw p-value ≤ 0.05) and a mean percentage methylation difference 385 between cases and controls greater than 5%. None of these differentially methylated loci were 386 significant after FDR corrections, however 94 DMPs had significant empirical p-values ≤ 0.05 387 after permutation analyses ( Supplementary Table S2 ). Out of these 94 DMPs, 29 were common 388 to the DMPs found when analysing the data from both sexes combined. 389
Approximately half of the DMP were clustered in differentially methylated regions 390 (DMRs). We found 17 DMRs with significant association with the ME/CFS phenotype (p-value regions were located nearby genes. 5 DMRs were found upstream of genes, 3 in promoters, 3 394 overlapping the 5' end and 1 the 3' end of genes, 10 inside introns, and 3 downstream of genes. 395 DMR length, in terms of number of CpG loci ranged between 2 and 10 (average 2.72). 7 DMRs 396 containing CpG loci identified as DMPs were detected in common between analyses of 397 methylation data from both sexes and from females only ( Figure 6) . 398
These results are in contrast with previous findings by our group, which revealed 399 thousands to tens of thousands of differentially methylated CpG loci associated with ME/CFS in 400 PBMCs, using the same 450K array 14, 18 . It is possible that differences between the targeted cell 401 populations (i.e. PBMCs vs. isolated T-cells) may have contributed to the differences in the 402 number of differentially methylated CpGs. The number of cell types within PBMCs may broaden 403 the spectrum of epigenetic marks and thus increase the number of possible associations with the 404 ME/CFS disease phenotype. Consistent with this idea, Brenu et al (2014) found 120 405 differentially methylated CpGs associated with ME/CFS in CD4+ T-cells (p<0.001) using the 406 450K array (n=25 ME/CFS, n=18 non-ME/CFS). This number of differentially methylated CpGs 407 is similar to the 133 DMPs we found in this study, which targeted a broader T-cell population 408 (including CD4+ and CD4-T-cells). However, the only overlap between our study and the study 409 from Brenu et al (2014) corresponded to the HLA-DQB1 (major histocompatibility complex, 410 class II, DQ beta 1) gene. HLA-DQB1 encodes a protein that is part of the DQ heterodimer, a 411 cell surface receptor that is essential in immune signalling. We found two contiguous 412 differentially methylated regions within an intron of this gene ( Supplementary Tables S1 and S3 , 413 Figure 6 ). One region was hypermethylated whereas the other was hypomethylated in the 414 ME/CFS group. Interestingly, the gene HLA-DQB1 contained cis-mQTLs significantly 415 associated with these two DMRs (see next section, as well as Supplementary Table S5 , and 416 Figure 6 ). Brenu et al. (2014) found CpG hypermethylation associated with the HLA-DQB1 417 gene, however the specific location of this association was not reported. Recent studies focusing 418 on CD4+ T-cells of patients affected by immune disorders such as rheumatoid arthritis 74 and 419 multiple sclerosis 75 have found differential methylation in HLA-DQB1. This result is consistent 420 with a potential immune dysregulation in ME/CFS. 421 (ATPase H+/K+ transporting beta subunit) ( Supplementary Table S1 ), are involved in the 424 regulation of cellular processes and cell signaling. This is in line with recent ME/CFS work that 425 observed differences in cellular metabolism in ME/CFS 76-78 . 426 Our results suggest that DNA methylation modifications in T-cells in ME/CFS are 427 associated with the cellular metabolism differences that are observed in the disease and may play 428 a role in the development of these phenotypic differences, however future work is required to 429 understand this relationship. 430 431 Genetic and epigenetic interactions associated with ME/CFS 432 All the DMPs identified according to empirical p-values had significant associations 433 (FDR corrected p-values < 0.05) with SNP genotypes (independent of disease phenotype). In 434 total there were 13,060 significant cis-mQTLs ( Supplementary Table S5 ). Figure 6 shows the 435 strongest SNP-DMPs cis-mQTLs associations (according to correlation coefficient R 2 ) in each of 436 the 7 DMP-containing DMRs that were common in analyses of methylation data from both sexes 437 and from females only. 438 SPATC1L (spermatogenesis and centriole associated 1 like) and DUSP22 (dual 439 specificity phosphatase 22) were the two genes containing cis-mQTLs with the largest 440 differentially methylated regions: 11 DMPs (7 hypermethylated probes in 5' UTR and 4 441 hypomethylated probes in 3' UTR region) in SPATC1L and 10 hypermethylated probes in the 5' 442 UTR of DUSP22 ( Supplementary Table S3 and Figure 6 ). While the exact function of SPATC1L 443 is not well understood, it has been previously associated with xenobiotic response and 444 differential methylation in the promoter of this gene is characteristic of certain ethnic groups in 445 human populations 79 . DUSP22 hypermethylation has also been observed in the 5' UTR region 446
in T-cells of rheumatoid arthritis patients 80 . In T-cells, DUSP22 is known to inhibit proliferation 447 and autoimmunity through inactivating Lck and preventing the activation of the T-cell receptor 448 81 . However, it remains to be confirmed how hypermethylation in the 5' UTR region affects the 449 overall activity of DUSP22 in T-cells of ME/CFS patients. 450 controls, n = 36; vs. ME/CFS cases, n = 43) that were also identified from analysis of data females alone 454 (healthy controls, n = 27; vs. ME/CFS cases, n = 34). Each panel shows (in descending order): 1) The 455 chromosomal location of the gene/DMR; 2) The position of the DMPs (green bars) and DMR (purple 456 bars) with respect to the gene (blue bars); 3) The mean percentage methylation difference between 457 ME/CFS cases (red) and controls (blue) at each DMP; 4) The most significant meQTL association (as 458 indicated by the R 2 and p-values) between SNP genotype and the individual percentage methylation at the 459 most significant DMP (as indicated by the p-value) within each DMR.
461
These results suggest that ME/CFS patients have differential methylation patterns in T-462 cells that are strongly correlated with the underlying genotype. Understanding the mechanisms of 463 these interactions is a promising direction of research in ME/CFS. 464 465
Conclusions

466
We identified over one hundred differentially methylated CpG loci associated with 467 ME/CFS in T lymphocytes. Approximately half of these were clustered in differentially 468 methylated regions of 500bp in size or less. Our data and analyses suggest that there is an 469 indirect role of genotype influencing DNA methylation patterns associated with ME/CFS. We 470 found no substantial large-effect direct associations of specific genotypes with ME/CFS disease 471 phenotype. Larger scale genome wide association studies are necessary to test for potential 472 small-effect associations between genotype and ME/CFS phenotype. 473 474 All of the methylation values at differentially methylated loci in T lymphocytes had 475 significant correlations with specific genotypes at neighboring SNPs (within a window of 1 476 Mbp), indicating that particular genetic backgrounds may influence methylation levels 477 differently in ME/CFS patients than in controls. The genomic elements associated with genetic 478 and epigenetic variants characteristic of ME/CFS patients in this study constitute targets for 479 future research. Understanding the molecular mechanisms of genetic-epigenetic interactions of 480 these targets will be key to develop new treatments for ME/CFS, and can serve as a model to 481 understand the molecular basis of related complex diseases. 482 circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic 512 fatigue syndrome. Cytokine 78, 27-36 (2016) . 513 focused genetic evaluation of immune and inflammation related genes with chronic 543 fatigue syndrome. Hum. Immunol. 76, 553-560 (2015) . 544 17. Smith, A. K., Fang, H., Whistler, T., Unger, E. R. & Rajeevan, M. S. Convergent genomic 545 studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome.
